ARYx Therapeutics (ARYx Therapeutics) ROCE % : 0.00% (As of Sep. 2010)

View and export this data going back to 2007. Start your Free Trial

What is ARYx Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ARYx Therapeutics's annualized ROCE % for the quarter that ended in Sep. 2010 was 0.00%.

ARYx Therapeutics ROCE % Historical Data

The historical data trend for ARYx Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARYx Therapeutics ROCE % Chart

ARYx Therapeutics Annual Data

Trend

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

ROCE %

Get a 7-Day Free Trial

-110.18

-79.91

-56.80

-63.17

-142.46

ARYx Therapeutics Quarterly Data
	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10
ROCE %	Get a 7-Day Free Trial															-225.56	-325.94	-682.52	-1,182.13	-

ARYx Therapeutics ROCE % Calculation

ARYx Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2009 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2009 )		(A: Dec. 2008 )		(A: Dec. 2009 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2009 )		(A: Dec. 2008 )		(A: Dec. 2009 )
	=	-31.238	/	( ( (51.148 - 11.019)	+	(12.406 - 8.681) )	/ 2 )
	=	-31.238	/	( (40.129	+	3.725)	/ 2 )
	=	-31.238	/	21.927
	=	-142.46 %

ARYx Therapeutics's ROCE % of for the quarter that ended in Sep. 2010 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2010 )		(Q: Jun. 2010 )		(Q: Sep. 2010 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2010 )		(Q: Jun. 2010 )		(Q: Sep. 2010 )
	=	-8.58	/	( ( (5.018 - 6.154)	+	(5.972 - 7.789) )	/ 2 )
	=	-8.58	/	( ( -1.136	+	-1.817 )	/ 2 )
	=	-8.58	/	-1.4765
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2010) EBIT data.

ARYx Therapeutics (OTCPK:ARYX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ARYx Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of ARYx Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ARYx Therapeutics (ARYx Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ARYx Therapeutics Inc (OTCPK:ARYX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6300 Dumbarton Circle, Fremont, CA, USA, 94555

Website

http://www.aryx.com

ARYx Therapeutics Inc is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.

Executives

Newhall Charles W Iii	10 percent owner	1119 ST PAUL ST, BALTIMORE MD 21202
C Richard Kramlich	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ryan D Drant	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Krishna Kittu Kolluri	10 percent owner
New Enterprise Associates 12, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea Partners 12, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 12 Gp, Llc	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Mark W Perry	10 percent owner
Patrick J Kerins	10 percent owner
Forest Baskett	10 percent owner
Growth Equity Opportunities Fund, Llc	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
M James Barrett	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Scott D Sandell	10 percent owner
Nicholas Galakatos	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

ARYx Therapeutics (ARYx Therapeutics) Headlines

No Headlines